Enhabit, Inc.

NYSE:EHAB Stock Report

Market Cap: US$365.6m

Enhabit Valuation

Is EHAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EHAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EHAB ($7.46) is trading below our estimate of fair value ($17.65)

Significantly Below Fair Value: EHAB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EHAB?

Key metric: As EHAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EHAB. This is calculated by dividing EHAB's market cap by their current revenue.
What is EHAB's PS Ratio?
PS Ratio0.4x
SalesUS$1.04b
Market CapUS$365.57m

Price to Sales Ratio vs Peers

How does EHAB's PS Ratio compare to its peers?

The above table shows the PS ratio for EHAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
CCRN Cross Country Healthcare
0.2x-5.3%US$341.3m
NRC National Research
3.1xn/aUS$442.1m
PFMT Performant Financial
1.9x9.0%US$238.0m
AIRS AirSculpt Technologies
1.9x9.2%US$369.0m
EHAB Enhabit
0.4x4.2%US$365.6m

Price-To-Sales vs Peers: EHAB is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does EHAB's PS Ratio compare vs other companies in the US Healthcare Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$78.15b
CVS CVS Health
0.2x4.6%US$70.18b
COR Cencora
0.2x6.4%US$47.23b
CNC Centene
0.2x5.5%US$29.19b
EHAB 0.4xIndustry Avg. 1.0xNo. of Companies31PS012345+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EHAB is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is EHAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EHAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: EHAB is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EHAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.46
US$8.65
+16.0%
8.9%US$10.00US$8.00n/a5
Nov ’25US$7.25
US$9.05
+24.8%
11.4%US$11.00US$8.00n/a5
Oct ’25US$7.54
US$9.21
+22.1%
10.9%US$11.00US$8.00n/a6
Sep ’25US$8.44
US$9.21
+9.1%
10.9%US$11.00US$8.00n/a6
Aug ’25US$10.05
US$9.18
-8.7%
14.3%US$12.00US$8.00n/a7
Jul ’25US$8.75
US$9.18
+4.9%
14.3%US$12.00US$8.00n/a7
Jun ’25US$9.19
US$9.32
+1.4%
13.2%US$12.00US$8.00n/a7
May ’25US$10.18
US$10.93
+7.4%
16.3%US$14.00US$8.50n/a7
Apr ’25US$11.29
US$10.93
-3.2%
16.3%US$14.00US$8.50n/a7
Mar ’25US$8.81
US$10.79
+22.4%
20.4%US$15.00US$8.00n/a7
Feb ’25US$10.27
US$10.79
+5.0%
20.4%US$15.00US$8.00n/a7
Jan ’25US$10.35
US$10.79
+4.2%
20.4%US$15.00US$8.00n/a7
Dec ’24US$10.93
US$10.25
-6.2%
23.2%US$15.00US$8.00n/a6
Nov ’24US$7.28
US$10.92
+50.0%
24.6%US$15.00US$7.00US$7.256
Oct ’24US$11.25
US$11.25
0%
24.3%US$16.00US$8.00US$7.546
Sep ’24US$12.63
US$11.36
-10.1%
22.4%US$16.00US$8.00US$8.447
Aug ’24US$13.58
US$13.31
-2.0%
22.1%US$17.00US$9.50US$10.058
Jul ’24US$11.50
US$13.94
+21.2%
25.4%US$20.00US$9.50US$8.758
Jun ’24US$11.94
US$14.79
+23.8%
21.1%US$20.00US$9.50US$9.197
May ’24US$12.40
US$15.57
+25.6%
19.7%US$20.00US$11.00US$10.187
Apr ’24US$13.91
US$16.00
+15.0%
17.4%US$20.00US$12.00US$11.298
Mar ’24US$14.85
US$16.14
+8.7%
18.3%US$20.00US$12.00US$8.817
Feb ’24US$15.47
US$15.86
+2.5%
16.3%US$20.00US$12.00US$10.277
Jan ’24US$13.16
US$15.50
+17.8%
17.0%US$20.00US$12.00US$10.356
Dec ’23US$13.92
US$16.25
+16.7%
15.9%US$20.00US$13.00US$10.934
Nov ’23US$12.96
US$17.25
+33.1%
15.5%US$20.00US$13.00US$7.284

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%